Endo to buy Par Pharmaceutical for $8.05 bn
Endo International will buy Par Pharmaceutical Holdings in a $8.05 billion deal that will strengthen Endo's generic drugs business, the companies said Monday.
May 18, 2015
0
3
Endo International will buy Par Pharmaceutical Holdings in a $8.05 billion deal that will strengthen Endo's generic drugs business, the companies said Monday.
May 18, 2015
0
3
In a win for consumers, the California Supreme Court ruled Thursday that settlement agreements between pharmaceutical companies that keep cheaper, generic drugs off the market may be illegal if they include excessive cash ...
May 7, 2015
0
10
(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.
Apr 30, 2015
0
8
Generic drug company Mylan rejected for the second time Monday a $40.1 billion takeover offer from Israeli pharmaceutical power Teva, just days after Mylan's own bid for rival Perrigo was rebuffed.
Apr 27, 2015
0
1
Scientists at the University of Liverpool have demonstrated that a drug for treating hepatitis B virus (HBV) could be mass-produced for only £24 ($36) per person per year, versus the current UK NHS price of £4,600, and ...
Apr 22, 2015
0
23
Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny ...
Apr 21, 2015
0
1
(HealthDay)—The first U.S. generic version of Copaxone (glatiramer acetate injection) has been approved by the Food and Drug Administration to treat multiple sclerosis.
Apr 17, 2015
0
2
In a deal that would combine two generic drugmakers that recently left the U.S. for Europe, Mylan says it wants to buy Perrigo for $205 per share, or $28.86 billion.
Apr 8, 2015
0
7
Patient access to generic prescription drugs and community pharmacies are both increasingly at risk due to inadequate reimbursement rates that fail to cover the cost of filling prescriptions, according to a new survey of ...
Apr 8, 2015
0
13
Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients.
Mar 6, 2015
0
9